Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 12;17(3):e80465.
doi: 10.7759/cureus.80465. eCollection 2025 Mar.

The Potential Renal Protective Effect of Transcatheter Aortic Valve Replacement

Deepa Soodi  1 , Paul Yeung  2 , Peter Umukoro  3 , Somto T Nwaedozie  4 , Rachel Gabor  5 , Eric DeJarlaris  5 , Param Sharma  1 , Romel Garcia-Montilla  6
Affiliations

The Potential Renal Protective Effect of Transcatheter Aortic Valve Replacement

Deepa Soodi et al. Cureus. .

Abstract

Background The incidence of aortic stenosis (AS) is steadily increasing, posing a significant healthcare burden. Transcatheter aortic valve replacement (TAVR) is being used more frequently to treat patients with symptomatic AS. This study evaluated long-term changes in renal function and mortality in TAVR patients over a period of up to three years, including those with normal creatinine (Cr) levels and those with chronic kidney disease (CKD). Methods We conducted a retrospective review of 270 patients who underwent TAVR between 2012 and 2017 at a rural tertiary referral center. Collected data included baseline serum Cr and estimated glomerular filtration rate (eGFR), with follow-up measurements taken at 30 days, six months, one year, two years, and three years post-TAVR. Patients were categorized into two groups: those with CKD and those without. Results Both groups showed similar improvements in eGFR at one month (6.3 mL/min/m², p < 0.001). However, by three months, eGFR levels returned to their pre-TAVR baseline. At the three-year mark, an average decline of 5.3 mL/min/m² was observed in both groups (p < 0.001). Despite CKD patients having worse kidney function throughout the study period, the extent of eGFR reduction was similar between the CKD and non-CKD groups, indicating that eGFR decline was independent of CKD status. Mortality rates were higher in CKD patients (56.9 (39%) vs. 24.6 (22%); p = 0.006). Multivariate analysis identified CKD as the most reliable predictor of mortality. Conclusions Renal function significantly improved at one month post-TAVR in both CKD and non-CKD patients. Although eGFR initially improved after TAVR, the subsequent decline was similar in both groups, suggesting that the reduction in eGFR is independent of CKD status. Cardiorenal syndrome, which can occur with AS, may improve with TAVR. These findings support the potential renoprotective effect of TAVR in patients with CKD.

Keywords: acute kidney injury; aortic stenosis; chronic kidney disease; renal failure; tavr.

PubMed Disclaimer

Conflict of interest statement

Human subjects: Consent for treatment and open access publication was obtained or waived by all participants in this study. Marshfield Clinic Research Institute Institutional Review Board issued approval IRB00000673. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Figures

Figure 1
Figure 1. Average eGFR following TAVR
eGFR, estimated glomerular filtration rate; TAVR, transcatheter aortic valve replacement
Figure 2
Figure 2. Estimated eGFR trends following TAVR procedure in CKD and non-CKD groups
CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; TAVR, transcatheter aortic valve replacement
Figure 3
Figure 3. Adjusted survival curves by baseline CKD following TAVR procedure
CKD, chronic kidney disease; TAVR, transcatheter aortic valve replacement
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Burden of valvular heart diseases: a population-based study. Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Lancet. 2006;368:1005–1011. - PubMed
    1. Transcatheter aortic valve replacement: a kidney's perspective. Cheungpasitporn W, Thongprayoon C, Kashani K. J Renal Inj Prev. 2016;5:1–7. - PMC - PubMed
    1. Correlates and causes of death in patients with severe symptomatic aortic stenosis who are not eligible to participate in a clinical trial of transcatheter aortic valve implantation. Ben-Dor I, Pichard AD, Gonzalez MA, et al. Circulation. 2010;122:0–42. - PubMed
    1. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. Leon MB, Smith CR, Mack M, et al. N Engl J Med. 2010;363:1597–1607. - PubMed
    1. Impact of kidney function on mortality after transcatheter valve implantation in patients with severe aortic valvular stenosis. Voigtländer L, Schewel J, Martin J, et al. Int J Cardiol. 2015;178:275–281. - PubMed

LinkOut - more resources